Arrowstreet Capital’s Celgene Corp CELG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-5,083,891
Closed -$505M 2025
2019
Q3
$505M Sell
5,083,891
-1,018,507
-17% -$96.8M 1.18% 10
2019
Q2
$564M Buy
6,102,398
+294,508
+5% +$28M 1.26% 8
2019
Q1
$548M Buy
5,807,890
+168,377
+3% +$14.7M 1.3% 11
2018
Q4
$361M Buy
5,639,513
+1,490,823
+36% +$110M 0.95% 18
2018
Q3
$371M Sell
4,148,690
-2,049,009
-33% -$181M 0.84% 26
2018
Q2
$492M Buy
6,197,699
+3,397
+0.1% +$282K 1.21% 12
2018
Q1
$553M Buy
6,194,302
+3,278,894
+112% +$315M 1.27% 13
2017
Q4
$304M Buy
2,915,408
+839,511
+40% +$94.7M 0.73% 31
2017
Q3
$303M Buy
2,075,897
+168,845
+9% +$23M 0.81% 31
2017
Q2
$248M Buy
1,907,052
+1,787,052
+1,489% +$219M 0.75% 31
2017
Q1
$14.9M Buy
+120,000
New +$14.4M 0.05% 320
2016
Q4
Sell
-39,900
Closed -$4.17M 2973
2016
Q3
$4.17M Buy
39,900
+34,600
+653% +$3.74M 0.01% 698
2016
Q2
$523K Buy
+5,300
New +$548K ﹤0.01% 1133
2015
Q4
Sell
-1,516,816
Closed -$164M 1720
2015
Q3
$164M Buy
1,516,816
+154,300
+11% +$19.1M 0.78% 21
2015
Q2
$158M Buy
1,362,516
+1,235,201
+970% +$141M 0.89% 17
2015
Q1
$14.7M Sell
127,315
-181,031
-59% -$21.6M 0.09% 218
2014
Q4
$34.5M Sell
308,346
-347,816
-53% -$36.7M 0.2% 112
2014
Q3
$62.2M Sell
656,162
-164,650
-20% -$14.9M 0.33% 81
2014
Q2
$70.5M Sell
820,812
-1,109,250
-57% -$84.4M 0.36% 65
2014
Q1
$135M Buy
1,930,062
+4,784
+0.2% +$379K 0.81% 28
2013
Q4
$163M Sell
1,925,278
-333,310
-15% -$26.4M 0.88% 21
2013
Q3
$174M Buy
2,258,588
+906,698
+67% +$63.5M 1.11% 12
2013
Q2
$79M Buy
+1,351,890
New +$81.4M 0.59% 46

Other funds holding CELG

Arrowstreet Capital's CELG Position: Q4 2019 in Review

Arrowstreet Capital sold out of Celgene Corp (CELG) in Q4 2019, closing a stake of 5,083,891 shares — an estimated $505M sold.

Arrowstreet Capital first reported a position in CELG in Q2 2013 and held it in 23 quarters. The position peaked at $564M in Q2 2019. 4 funds tracked by Wall St. Rank hold CELG as of Q4 2019.

  • Arrowstreet Capital reported no remaining Celgene Corp position as of Q4 2019 after selling out during the quarter.
  • Arrowstreet Capital sold 5,083,891 Celgene Corp shares in Q4 2019, an estimated $505M.
  • Arrowstreet Capital first reported a position in Celgene Corp in Q2 2013 and held it in 23 quarters.
  • Arrowstreet Capital's Celgene Corp position peaked at $564M in Q2 2019.
  • 4 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2019.

Based on Arrowstreet Capital's 13F filing for Q4 2019, filed 13 Feb 2020.